Icahn School of Medicine at Mount Sinai
AACR 2024 Insights: "Linvoseltamab, a BCMA-Targeted BsAb, in Pts With R/R Myeloma Including Difficult-to-Treat Subgroups"
By
Icahn School of Medicine at Mount Sinai
FEATURING
Sundar Jagannath
By
Icahn School of Medicine at Mount Sinai
FEATURING
Sundar Jagannath
Login to view comments.
Click here to Login